Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$51.97
-0.53 (-1.01%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $19.9M · quality 43.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.8B
P/E
29.4x
↑EV/EBITDA
21.1x
↑ROE
16.7%
↑Gross Margin
54.1%
↑Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.8%
FCF CAGR
+720.6%
FCF margin
4.2%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.22B · net income $203.9M · FCF $50.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.22B | $1.22B | $1.08B | $932.1M | $676.6M |
| Net Income | $203.9M | $203.9M | $177.4M | $184.8M | $156.5M |
| EBITDA | $277.3M | $277.3M | $242.1M | $250.5M | $218.8M |
| EPS | 1.86 | 1.86 | 1.58 | 1.65 | 1.40 |
| Gross Margin | 54.1% | 54.1% | 50.2% | 56.7% | 55.5% |
| Operating Margin | 26.5% | 26.5% | 21.7% | 27.7% | 28.1% |
| Net Margin | 16.7% | 16.7% | 16.5% | 19.8% | 23.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.41 | 0.43 | 0.29 |
| Current Ratio | 1.79 | 1.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $50.8M | $50.8M | $1.5M | $19.9M | $91916.71 |
| Returns | |||||
| ROE | 16.7% | 16.7% | 16.1% | 17.8% | 17.4% |
| Valuation | |||||
| P/E | 29.36 | 29.36 | 22.72 | 42.79 | 53.31 |
| EV/EBITDA | 21.09 | 21.09 | 16.20 | 30.59 | 36.52 |
| P/B | 4.68 | 4.68 | 3.66 | 7.60 | 9.30 |
| Growth & Yield | |||||
| Revenue Growth | 13.3% | 13.3% | 15.7% | 37.8% | — |
| EPS Growth | 17.7% | 17.7% | -4.2% | 17.9% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
35.3%
EPS terminal req.
$4.61
Spread vs growth
-17.6%
5Y implied EPS CAGR
24.6%
EPS terminal req.
$5.58
Spread vs growth
-6.9%
10Y implied EPS CAGR
17.1%
EPS terminal req.
$8.99
Spread vs growth
0.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.8%
Start / end P/E
29.8x → 27.9x
EPS bridge
1.58 → 1.86
Residual
-1.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.